Rosiglitazone (Avandia/Avandamet) and cardiovascular risk

Hdl Handle:
http://hdl.handle.net/10147/129144
Title:
Rosiglitazone (Avandia/Avandamet) and cardiovascular risk
Authors:
Irish Medicines Board (IMB)
Publisher:
Irish Medicines Board (IMB)
Journal:
MIMS Ireland
Issue Date:
20-Aug-2010
URI:
http://hdl.handle.net/10147/129144
Item Type:
Guideline
Language:
en
Keywords:
MEDICINES; REGULATION

Full metadata record

DC FieldValue Language
dc.contributor.authorIrish Medicines Board (IMB)en
dc.date.accessioned2011-05-05T15:26:09Z-
dc.date.available2011-05-05T15:26:09Z-
dc.date.issued2010-08-20-
dc.identifier.urihttp://hdl.handle.net/10147/129144-
dc.language.isoenen
dc.publisherIrish Medicines Board (IMB)en
dc.subjectMEDICINESen
dc.subjectREGULATIONen
dc.titleRosiglitazone (Avandia/Avandamet) and cardiovascular risken
dc.typeGuidelineen
dc.identifier.journalMIMS Irelanden
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.